Priority Of Merck's Integration Of Schering Is Retaining Top R&D Talent, Kim Says
This article was originally published in The Pink Sheet Daily
Identifying and retaining key Schering-Plough R&D personnel is a top priority once the mega-merger is complete, Merck says.
You may also be interested in...
The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.
Schering-Plough's investigational thrombin receptor antagonist has the potential to be a transformative commercial opportunity for the drug maker. The product is one of five pipeline "stars" management highlighted during an R&D update Nov. 24, and one investors are keeping an especially close eye on
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.